BTG (OTCMKTS:BTGGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “
Shares of BTG (OTCMKTS:BTGGF) remained flat at $$9.85 on Wednesday. BTG has a 52-week low of $6.74 and a 52-week high of $10.04.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.